This is consistent with prior reports on the good prognosis of this subgroup.23 For ovarian high-grade serous carcinoma, alterations in actionable genes CCNE1 (20%), NF1 (12%), PIK3CA (18%), and PTEN (8%) were the most common in TCGA; however, only one protocol patient with ovarian cancer had a CCNE1 amplification, whereas no alterations were observed in the other genes (Data Supplement). This evidence concerns the gene NF1 and serous adenocarcinoma.